文献速递青光眼

他达拉非治疗下尿路症状与青光眼风险的多国队列研究

Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study.
PubMed 文献 · Br J Ophthalmol · 2026-08-04

这项多国回顾性队列研究利用TriNetX数据库,纳入2012至2022年间有下尿路症状(LUTS)的40岁以上男性,经倾向评分匹配后比较他达拉非使用者与非PDE5i使用者。结果显示他达拉非使用与青光眼风险升高相关(HR 1.22;95%CI 1.12-1.33),主要表现为眼压升高、原发性开角型青光眼及启动青光眼治疗的风险增加。

要点

  • 他达拉非使用与总体青光眼风险升高相关(HR 1.22;95%CI 1.12-1.33)。
  • 眼压升高、原发性开角型青光眼及启动青光眼治疗风险均升高。
  • 低眼压性青光眼和原发性闭角型青光眼无显著关联。

核心结论

  • 在有LUTS的男性中,他达拉非使用与非PDE5i使用相比与青光眼风险升高相关。
  • 建议考虑进行眼科评估和随访,尤其是有青光眼危险因素的患者。

研究设计与样本

  • 多国回顾性队列研究,使用TriNetX数据库。
  • 纳入2012至2022年间有LUTS病史的40岁以上男性,排除入组前有青光眼病史者。
  • 分为他达拉非组和非PDE5i组,经1:1倾向评分匹配平衡年龄、种族、合并症、肾功能和合并用药。
  • 队列包括36 927名他达拉非使用者和36 927名匹配的非PDE5i使用者。

主要发现

  • 随访至5年,他达拉非使用与青光眼风险升高相关(HR 1.22;95%CI 1.12至1.33)。
  • 眼压升高风险升高(HR 1.32;95%CI 1.06至1.65)。
  • 原发性开角型青光眼风险升高(HR 1.33;95%CI 1.05至1.67)。
  • 启动青光眼治疗的风险升高(HR 1.33;95%CI 1.20至1.47)。
  • 低眼压性青光眼和原发性闭角型青光眼无显著关联。

关键数值与推荐

  • 他达拉非组与非PDE5i组比较,青光眼总体HR 1.22(95%CI 1.12至1.33)。
  • 眼压升高HR 1.32(95%CI 1.06至1.65)。
  • 原发性开角型青光眼HR 1.33(95%CI 1.05至1.67)。
  • 启动青光眼治疗HR 1.33(95%CI 1.20至1.47)。
  • 5年累积发病率他达拉非组3.93% vs 非PDE5i组3.16%(p<0.001)。

临床怎么用

  • 对有LUTS使用他达拉非的男性,可考虑眼科评估和随访。
  • 尤其应关注有青光眼危险因素的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the association between tadalafil use for lower urinary tract symptoms (LUTS) and the risk of developing glaucoma. METHODS: This multinational, retrospective cohort study was conducted using the TriNetX database. Men aged ≥40 years with a history of LUTS were enrolled between 2012 and 2022. Individuals with a history of glaucoma prior to cohort entry were excluded. Participants were categorised into the tadalafil group and the non-phosphodiesterase type 5 inhibitor (non-PDE5i) group. Propensity score matching (1:1) was conducted to balance age, race, comorbidities, renal function and concomitant medications. Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment. RESULTS: The cohort included 36 927 tadalafil users and 36 927 matched non-PDE5i users. Up to 5 years, tadalafil use was associated with an increased risk of glaucoma compared with non-PDE5i use (HR 1.22; 95% CI 1.12 to 1.33). Elevated risks were observed for ocular hypertension (HR 1.32; 95% CI 1.06 to 1.65), primary open-angle glaucoma (HR 1.33; 95% CI 1.05 to 1.67) and initiation of glaucoma treatment (HR 1.33; 95% CI 1.20 to 1.47). No significant associations were found for low-tension or primary angle-closure glaucoma. Tadalafil users had a higher 5-year cumulative incidence than non-users (3.93% vs 3.16%; p<0.001), with consistent risk in men >50 years, white population and across comorbidities, remaining robust to 1-, 3- and 6-month lag times. CONCLUSIONS: Tadalafil was associated with increased risk of glaucoma compared with non-PDE5i in males with LUTS. Ophthalmic evaluation and follow-up may be considered, particularly in patients with risk factors for glaucoma.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hsia Y, Tsai CY, Hung SC, et al. Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study. Br J Ophthalmol. 2026. PMID: 42552102. doi:10.1136/bjo-2026-329957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。